Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.
Bicyclol is used for the treatment of chronic hepatitis B in China. In this study, the effects of bicyclol (100 or 300 mg kg(-1), p.o.) on serum and liver lipid contents were investigated in both normal and experimentally induced hypercholesterolaemic mice. Hypercholesterolaemia was induced by either oral administration of cholesterol/bile salt or feeding a diet containing lard/cholesterol. Daily administration of bicyclol for 7 days dose-dependently increased the serum triglyceride level (29-80%) but slightly decreased the hepatic total cholesterol level (12-17%) in normal mice. Co-administration of bicyclol with cholesterol/bile salt decreased the hepatic triglyceride and total cholesterol levels (7-15% and 25-31%, respectively), when compared with the drug-untreated and cholesterol/bile salt-treated group. Bicyclol treatment for 7 days decreased hepatic triglyceride (5-76%) and total cholesterol (5-48%) levels in mice fed with high-fat/cholesterol diet. In contrast, bicyclol treatment increased the serum triglyceride level (18-77%) in mice treated with cholesterol/bile salt or fed with high-fat/cholesterol diet. Bicyclol treatment also caused an increase in hepatic index of normal and hypercholesterolaemic mice (3-32%). The results indicate that bicyclol treatment can invariably decrease hepatic lipid levels and increase serum triglyceride levels in normal and hypercholesterolaemic mice.
Pan
Si-Yuan
SY
Department of Pharmacology, Beijing University of Chinese Medicine, Beijing 100102, China. zlyu@hkbu.edu.hk
Dong
Hang
H
Yu
Zhi-Ling
ZL
Zhao
Xin-Ye
XY
Xiang
Chun-Jing
CJ
Wang
Hui
H
Fong
Wang-Fun
WF
Ko
Kam-Ming
KM
D000704:Analysis of Variance; D000818:Animals; D001647:Bile Acids and Salts / Q000008:administration & dosage; D001713:Biphenyl Compounds / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D034242:Cyclooctanes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D011345:Fenofibrate / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000097:blood* / Q000139:chemically induced / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007441:Intubation, Gastrointestinal; D008055:Lipids / Q000032:analysis*; D008099:Liver / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D013607:Tablets; D013997:Time Factors; D014280:Triglycerides / Q000097:blood* / Q000378:metabolism
D001647:Bile Acids and Salts; D001713:Biphenyl Compounds; D002791:Cholesterol, Dietary; D034242:Cyclooctanes; D000960:Hypolipidemic Agents; D008055:Lipids; D013607:Tablets; D014280:Triglycerides; C511097:dibenzocyclooctadiene; C477843:bicyclol; D002784:Cholesterol; D011345:Fenofibrate